Prostate cancer prevention: review of target populations, pathological biomarkers, and chemopreventive agents.
暂无分享,去创建一个
[1] C. Myers,et al. Lipoxygenase Inhibition in Prostate Cancer , 1999, European Urology.
[2] D. Mccormick,et al. Chemoprevention of Hormone-Dependent Prostate Cancer in the Wistar-Unilever Rat , 1999, European Urology.
[3] N. Weigel,et al. Vitamin D and Prostate Cancer , 1999, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.
[4] D. Peehl. Vitamin D and Prostate Cancer Risk , 1999, European Urology.
[5] P H Bartels,et al. Chromatin texture signatures in nuclei from prostate lesions. , 1998, Analytical and quantitative cytology and histology.
[6] P H Bartels,et al. Machine vision in the detection of prostate lesions in histologic sections. , 1998, Analytical and quantitative cytology and histology.
[7] P. Bartels,et al. Statistical histometry of the basal cell/secretory cell bilayer in prostatic intraepithelial neoplasia. , 1998, Analytical and quantitative cytology and histology.
[8] E. Rimm,et al. Study of prediagnostic selenium level in toenails and the risk of advanced prostate cancer. , 1998, Journal of the National Cancer Institute.
[9] J. Brooks,et al. CG island methylation changes near the GSTP1 gene in prostatic intraepithelial neoplasia. , 1998, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[10] E. Constant,et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. , 1998 .
[11] P H Bartels,et al. Nuclear morphometry in solar keratosis. , 1998, Analytical and quantitative cytology and histology.
[12] E. Hawk,et al. Development of new cancer chemoprevention agents: role of pharmacokinetic/pharmacodynamic and intermediate endpoint biomarker monitoring. , 1998, Clinical chemistry.
[13] J. Crowley,et al. Chemoprevention of prostate cancer: The prostate cancer prevention trial , 1997, The Prostate.
[14] G. Miller,et al. Three synthetic vitamin D analogues induce prostate-specific acid phosphatase and prostate-specific antigen while inhibiting the growth of human prostate cancer cells in a vitamin D receptor-dependent fashion. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[15] S. Venitt,et al. Detection of telomerase activity in human prostate: a diagnostic marker for prostatic cancer? , 1997, British journal of urology.
[16] D. Mahvi,et al. Potential use of image analysis for the evaluation of cellular predicting factors for therapeutic response in breast cancers. , 1997, Analytical and quantitative cytology and histology.
[17] A. Partin,et al. Incidence of high-grade prostatic intraepithelial neoplasia in sextant needle biopsy specimens. , 1997, Urology.
[18] G. Coetzee,et al. Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. , 1997, Journal of the National Cancer Institute.
[19] Bruce W. Turnbull,et al. Effects of Selenium Supplementation for Cancer Prevention in Patients With Carcinoma of the Skin: A Randomized Controlled Trial , 1996 .
[20] G. Kelloff,et al. Prostate cancer prevention: investigational approaches and opportunities. , 1996, Cancer research.
[21] D A Meyers,et al. Major Susceptibility Locus for Prostate Cancer on Chromosome 1 Suggested by a Genome-Wide Search , 1996, Science.
[22] V. Steele,et al. Strategies for identification and clinical evaluation of promising chemopreventive agents. , 1996, Oncology.
[23] D. Schaid,et al. Allelic imbalance and microsatellite instability in prostatic adenocarcinoma. , 1996, Cancer research.
[24] J. Isaacs,et al. Antiangiogenic treatment with linomide as chemoprevention for prostate, seminal vesicle, and breast carcinogenesis in rodents. , 1996, Cancer research.
[25] M. Soloway,et al. Histopathological effects of androgen deprivation in prostatic cancer. , 1996, Seminars in urologic oncology.
[26] K. Griffiths,et al. The preventive role of diet in prostatic disease. , 1996, British journal of urology.
[27] R. Amato,et al. What does the pathology report really mean? , 1996, Seminars in urologic oncology.
[28] G A Colditz,et al. Intake of carotenoids and retinol in relation to risk of prostate cancer. , 1995, Journal of the National Cancer Institute.
[29] D. Bostwick,et al. Chromosomal anomalies in prostatic intraepithelial neoplasia and carcinoma detected by fluorescence in situ hybridization. , 1995, Cancer research.
[30] D. Bostwick,et al. Prostatic intraepithelial neoplasia is a risk factor for adenocarcinoma: predictive accuracy in needle biopsies. , 1995, The Journal of urology.
[31] P. Bartels,et al. Prostatic intraepithelial neoplasia. Quantitation of the basal cell layer with machine vision system. , 1995, Pathology, research and practice.
[32] L. Liotta,et al. Allelic loss on chromosome 8p12-21 in microdissected prostatic intraepithelial neoplasia. , 1995, Cancer research.
[33] M. S. Rhyu. Telomeres, telomerase, and immortality. , 1995, Journal of the National Cancer Institute.
[34] M. Brawer,et al. Topography of neovascularity in human prostate carcinoma , 1995, Cancer.
[35] J. Brooks,et al. Molecular genetics and chromosomal alterations in prostate cancer , 1995 .
[36] David G. Bostwick,et al. High grade prostatic intraepithelial neoplasia. The most likely precursor of prostate cancer , 1995 .
[37] T. H. van der Kwast,et al. Interphase cytogenetics of prostatic adenocarcinoma and precursor lesions: Analysis of 25 radical prostatectomies and 17 adjacent prostatic intraepithelial neoplasias , 1995, Genes, chromosomes & cancer.
[38] J. Liehr,et al. Induction of a DNA adduct detectable by 32P-postlabeling in the dorsolateral prostate of NBL/Cr rats treated with estradiol-17 beta and testosterone. , 1995, Carcinogenesis.
[39] A. Kirschenbaum. Management of hormonal treatment effects , 1995 .
[40] C B Harley,et al. Specific association of human telomerase activity with immortal cells and cancer. , 1994, Science.
[41] P. Harrison,et al. The selenium metabolite selenodiglutathione induces p53 and apoptosis: relevance to the chemopreventive effects of selenium? , 1994, Carcinogenesis.
[42] D. Tindall,et al. Antagonism of androgen action in prostate tumor cells by retinoic acid , 1994, The Prostate.
[43] D. Bostwick,et al. Potential markers of prostate cancer aggressiveness detected by fluorescence in situ hybridization in needle biopsies. , 1994, Cancer research.
[44] D. Bostwick,et al. Decrease of prostatic intraepithelialneoplasia following androgen deprivation therapy in patients with stage T3 carcinoma treated by radical prostatectomy , 1994 .
[45] D. Bostwick,et al. Loss of chromosome arm 8p loci in prostate cancer: Mapping by quantitative allelic imbalance , 1994, Genes, chromosomes & cancer.
[46] D. Grignon,et al. Allelic loss in locally metastatic, multisampled prostate cancer. , 1994, Cancer research.
[47] Schwartz Gg,et al. Human prostate cancer cells: inhibition of proliferation by vitamin D analogs. , 1994 .
[48] N. Hay,et al. Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation. , 1994, Cancer research.
[49] M. Sporn,et al. Histogenesis of induced prostate and seminal vesicle carcinoma in Lobund-Wistar rats: a system for histological scoring and grading. , 1994, Cancer research.
[50] T. Stamey,et al. Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. , 1994, Cancer research.
[51] H. Adlercreutz,et al. Plasma concentrations of phyto-oestrogens in Japanese men , 1993, The Lancet.
[52] E. Rimm,et al. A prospective study of dietary fat and risk of prostate cancer. , 1993, Journal of the National Cancer Institute.
[53] P. Walsh,et al. Homozygous deletion and frequent allelic loss of chromosome 8p22 loci in human prostate cancer. , 1993, Cancer research.
[54] J. Epstein,et al. Significance of high-grade prostatic intraepithelial neoplasia on needle biopsy. , 1993, Human pathology.
[55] G. Wilding,et al. Randomized Phase I Chemoprevention Dose-Seeking Study of α-Difluoromethylornithine , 1993 .
[56] H. Adlercreutz,et al. Genistein, a dietary-derived inhibitor of in vitro angiogenesis. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[57] M. Sporn,et al. Expression of sulfated glycoprotein 2 is associated with carcinogenesis induced by N-nitroso-N-methylurea in rat prostate and seminal vesicle. , 1993, Cancer research.
[58] K. Pienta,et al. Treatment of prostate cancer in the rat with the synthetic retinoid fenretinide. , 1993, Cancer research.
[59] M. Pike,et al. 5-alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males , 1992, The Lancet.
[60] M Petein,et al. Morphonuclear relationship between prostatic intraepithelial neoplasia and cancers as assessed by digital cell image analysis. , 1991, American journal of clinical pathology.
[61] T. Shirai,et al. Induction of invasive carcinomas of the seminal vesicles and coagulating glands of F344 rats by administration of N-methylnitrosourea or N-nitrosobis(2-oxopropyl)amine and followed by testosterone propionate with or without high-fat diet. , 1991, Carcinogenesis.
[62] U. Bergerheim,et al. Deletion mapping of chromosomes 8, 10, and 16 in human prostatic carcinoma , 1991, Genes, chromosomes & cancer.
[63] R. Montironi,et al. Quantitative analysis of prostatic intraepithelial neoplasia on tissue sections. , 1990, Analytical and quantitative cytology and histology.
[64] R. Peto,et al. Serum selenium and subsequent risk of cancer among Finnish men and women. , 1990, Journal of the National Cancer Institute.
[65] I. Leav,et al. Biochemical alterations in sex hormone-induced hyperplasia and dysplasia of the dorsolateral prostates of Noble rats. , 1988, Journal of the National Cancer Institute.
[66] R. Coates,et al. Serum levels of selenium and retinol and the subsequent risk of cancer. , 1988, American journal of epidemiology.
[67] W. Ellis,et al. Effectiveness of complete versus partial androgen withdrawal therapy for the treatment of prostatic cancer as studied in the Dunning R-3327 system of rat prostatic adenocarcinomas. , 1985, Cancer research.
[68] W. Willett,et al. PREDIAGNOSTIC SERUM SELENIUM AND RISK OF CANCER , 1983, The Lancet.
[69] G. Miller,et al. Strategies for chemoprevention of prostate cancer , 1999, Prostate Cancer and Prostatic Diseases.
[70] C. Boone,et al. Biomarker end-points in cancer chemoprevention trials. , 1997, IARC scientific publications.
[71] D. Grignon,et al. Age and racial distribution of prostatic intraepithelial neoplasia. , 1996, European urology.
[72] R. Montironi,et al. Precursors of prostatic cancer: progression, regression and chemoprevention. , 1996, European urology.
[73] P. Nelson,et al. Chemoprevention for prostatic intraepithelial neoplasia. , 1996, European urology.
[74] P H Bartels,et al. Analysis of the capillary architecture in the precursors of prostate cancer: recent findings and new concepts. , 1996, European urology.
[75] D. Bostwick,et al. Potential markers of aggressiveness in prostatic intraepithelial neoplasia detected by fluorescence in situ hybridization. , 1996, European urology.
[76] G. Mariuzzi,et al. Quantitative study of ductal breast cancer progression. A progression index (P.I.) for premalignant lesions and in situ carcinoma. , 1996, Pathology, research and practice.
[77] E. Crawford,et al. The role of prostate‐specific antigen in the chemoprevention of prostate cancer , 1996, Journal of cellular biochemistry. Supplement.
[78] V. Steele,et al. Surrogate endpoint biomarkers for phase II cancer chemoprevention trials. , 1994, Journal of cellular biochemistry. Supplement.
[79] D. Bostwick,et al. Decrease of prostatic intraepithelial neoplasia following androgen deprivation therapy in patients with stage T3 carcinoma treated by radical prostatectomy. , 1994, Urology.
[80] C. Boone,et al. Development of surrogate endpoint biomarkers for clinical trials of cancer chemopreventive agents: relationships to fundamental properties of preinvasive (intraepithelial) neoplasia. , 1994, Journal of cellular biochemistry. Supplement.
[81] D. Albanes,et al. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. , 1994, The New England journal of medicine.
[82] R. Montironi,et al. Quantitative characterization of the frequency and location of cell proliferation and death in prostate pathology. , 1994, Journal of cellular biochemistry. Supplement.
[83] D. Bostwick. Target populations and strategies for chemoprevention trials of prostate cancer. , 1994, Journal of cellular biochemistry. Supplement.
[84] Bostwick Dg. Target populations and strategies for chemoprevention trials of prostate cancer. , 1994 .
[85] D. Newling,et al. Panel discussion 2 , 1994 .
[86] Boone Cw,et al. Development of surrogate endpoint biomarkers for clinical trials of cancer chemopreventive agents: relationships to fundamental properties of preinvasive (intraepithelial) neoplasia. , 1994 .
[87] T. Stamey,et al. Vitamin A regulates proliferation and differentiation of human prostatic epithelial cells , 1993, The Prostate.
[88] R. Burk,et al. Regulation of selenoproteins. , 1993, Annual review of nutrition.
[89] G. Wilding,et al. Randomized phase I chemoprevention dose-seeking study of alpha-difluoromethylornithine. , 1993, Journal of the National Cancer Institute.
[90] D. Kadmon,et al. Chemoprevention in prostate cancer: The role of difluoromethylornithine (DFMO) , 1992, Journal of cellular biochemistry. Supplement.
[91] G. Gormley,et al. Chemoprevention strategies for prostate cancer: The role of 5α‐reductase inhibitors , 1992 .
[92] Morris Pollard,et al. The lobund‐wistar rat model of prostate cancer , 1992, Journal of cellular biochemistry. Supplement.
[93] R. Atherton,et al. A study of cAMP binding proteins on intact and disrupted sperm cells using 8‐azidoadenosine 3′,5′‐cyclic monophoshate , 1982, Journal of cellular biochemistry.